NASDAQ:EARS - Auris Medical Stock Price, Forecast & News

Auris Medical trades on the NASDAQ under the ticker symbol "EARS."

Auris Medical shares reverse split on the morning of Wednesday, May 1st 2019. The 1-20 reverse split was announced on Tuesday, April 30th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 30th 2019. An investor that had 100 shares of Auris Medical stock prior to the reverse split would have 5 shares after the split.

Auris Medical Holding Ltd (NASDAQ:EARS) posted its earnings results on Thursday, May, 11th. The biotechnology company reported ($4.40) EPS for the quarter, missing the consensus estimate of ($2.80) by $1.60. View Auris Medical's Earnings History.

Auris Medical is scheduled to release their next quarterly earnings announcement on Thursday, December 19th 2019. View Earnings Estimates for Auris Medical.

1 brokerages have issued twelve-month price objectives for Auris Medical's shares. Their forecasts range from $100.00 to $100.00. On average, they expect Auris Medical's stock price to reach $100.00 in the next twelve months. This suggests a possible upside of 7,146.4% from the stock's current price. View Analyst Price Targets for Auris Medical.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Auris Medical in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Auris Medical.

Media stories about EARS stock have been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Auris Medical earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Auris Medical.

Auris Medical saw a decline in short interest during the month of November. As of November 29th, there was short interest totalling 5,700 shares, a decline of 19.7% from the November 14th total of 7,100 shares. Based on an average trading volume of 151,900 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.4% of the shares of the stock are short sold. View Auris Medical's Current Options Chain.

Some companies that are related to Auris Medical include Pivot Pharmaceuticals (PVOTF), Lipocine (LPCN), HST Global (HSTC), Rexahn Pharmaceuticals (REXN), GT Biopharma (GTBP), Integrated BioPharma (INBP), Reliv International (RELV), DelMar Pharmaceuticals (DMPI), Novus Therapeutics (NVUS), Tetraphase Pharmaceuticals (TTPH), X T L Biopharmaceuticals (XTLB), Acura Pharmaceuticals (ACUR), BENITEC BIOPHAR/S (BNTC), Capricor Therapeutics (CAPR) and Tonix Pharmaceuticals (TNXP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Auris Medical investors own include Helios and Matheson Analytics (HMNY), TransEnterix (TRXC), Anavex Life Sciences (AVXL), Rigel Pharmaceuticals (RIGL), RXi Pharmaceuticals (RXII), Flexion Therapeutics (FLXN), Sophiris Bio (SPHS), Iconix Brand Group (ICON), Magnegas Applied Tchnlgy Sltns (MNGA) and Novavax (NVAX).

Auris Medical's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Sabby Management LLC (8.96%).

EARS stock was bought by a variety of institutional investors in the last quarter, including Sabby Management LLC.

Shares of EARS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EARS stock can currently be purchased for approximately $1.38.

Auris Medical has a market capitalization of $2.58 million. The biotechnology company earns $-11,750,000.00 in net income (profit) each year or ($14.80) on an earnings per share basis. Auris Medical employs 9 workers across the globe.View Additional Information About Auris Medical.

The official website for Auris Medical is http://www.aurismedical.com/.

Auris Medical's mailing address is BAHNHOFSTRASSE 21, ZUG V8, 6300. The biotechnology company can be reached via phone at 41-41-729-7194 or via email at [email protected]